Journal
CANCER AND METASTASIS REVIEWS
Volume 33, Issue 2-3, Pages 567-579Publisher
SPRINGER
DOI: 10.1007/s10555-013-9472-2
Keywords
Androgen receptor; Prostate cancer; CYP17; Abiraterone; Enzalutamide
Categories
Funding
- Cancer Research UK
- Experimental Cancer Medicine Centre
- National Institute for Health Research Biomedical Research Centre
Ask authors/readers for more resources
After decades of limited success in the treatment of castration-resistant prostate cancer (CRPC), five novel therapeutics were granted Food and Drug Administration regulatory approval in the last 4 years based on several randomized phase III studies that have reported a survival benefit. Among them, two drugs targeting the androgen receptor pathway, namely abiraterone acetate and enzalutamide, have demonstrated that targeting androgen signalling following progression to classical androgen blockade continues to be an effective strategy despite the emergence of resistance mechanisms to sequential treatments. In addition to these two approved drugs, several other promising agents that block steroidogenesis interact with the androgen receptor or modulate post-receptor signal transduction that are undergoing clinical evaluation. This issue reviews the current data and the state of development of novel androgen receptor-targeting drugs and further discusses how this revolution in therapeutic armamentarium for the treatment of CRPC has raised challenges for clinicians about the optimal usage of these compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available